The herpes zoster subunit vaccine

@article{Cunningham2016TheHZ,
  title={The herpes zoster subunit vaccine},
  author={Anthony L Cunningham},
  journal={Expert Opinion on Biological Therapy},
  year={2016},
  volume={16},
  pages={265 - 271}
}
  • A. Cunningham
  • Published 2016
  • Medicine
  • Expert Opinion on Biological Therapy
ABSTRACT Introduction: Herpes zoster (HZ) causes severe pain and rash in older people and may be complicated by prolonged pain (postherpetic neuralgia; PHN). Areas covered: HZ results from reactivation of latent varicella-zoster virus (VZV) infection, often associated with age related or other causes of decreased T cell immunity. A concentrated live attenuated vaccine boosts this immunity and provides partial protection against HZ, but this decreases with age and declines over 5-8 years. The… Expand
Vaccine profile of herpes zoster (HZ/su) subunit vaccine
TLDR
A new HZ subunit (HZ/su) vaccine combines a key surface VZV glycoprotein (E) with a T cell-boosting adjuvant system (AS01B) and is administered by two intramuscular injections two months apart and will have a major impact on HZ management. Expand
A novel nonlive, adjuvanted herpes zoster subunit vaccine: a report on the emerging clinical data and safety profile
TLDR
The aim of this review was to describe the epidemiological data, HZ and PHN risks and their impact on the social life and common life of infected people, and ZVL and HZ/su vaccine development including various clinical trials and efficacy, safety, and tolerability profiles. Expand
Tale of two vaccines: differences in response to herpes zoster vaccines.
  • A. Gershon
  • Medicine
  • The Journal of clinical investigation
  • 2018
TLDR
Differences in immunologic responses induced by two HZ vaccines paralleled the observed clinical protection of the two zoster vaccines, with HZ/su being superior to HZ, and seem to explain immunologically why the new subunit vaccine outperforms the live vaccine. Expand
Herpes zoster vaccination in systemic lupus erythematosus: the current status
  • C. Mok
  • Medicine
  • Human vaccines & immunotherapeutics
  • 2019
TLDR
The recent availability of the non-live subunit and inactivated herpes zoster vaccines has provided more opportunities for SLE patients to be protected against this viral infection. Expand
Zoster vaccination in older adults: efficacy and public health implications.
TLDR
Those vaccines that possess the ability to enhance antigen presentation and reverse memory T cell exhaustion, as well as diminish the immune suppressive effects of regulatory T cells, are most likely to be effective in older adults. Expand
Shingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine
TLDR
HZ/su significantly reduced the risk of developing herpes zoster by more than 90% as compared with placebo and displayed a comparable adverse effect profile, based on published immunogenicity, efficacy, and safety data. Expand
Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient
TLDR
A 79-year-old man with chronic lymphocytic leukaemia presented with fever and a widespread vesicular rash and died on day 25 after developing respiratory and renal failure and disseminated varicella zoster infection. Expand
Immune responses to zoster vaccines
TLDR
It is concluded that the immunologic data parallel and support the higher efficacy over time of RZV compared with ZVL, and that protection is not diminished by the age of the vaccinee and has not waned significantly during 4 years of follow-up. Expand
Assessment of the potential public health impact of Herpes Zoster vaccination in Germany
TLDR
The candidate HZ/su vaccine demonstrated superior public health impact compared with ZVL, and was estimated to reduce the number of HZ cases by 725,233, 533,162 and 486,794 in the 3 age cohorts, respectively, over the remaining lifetime since vaccination. Expand
Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy
TLDR
This review summarizes recent findings in the development of HCMV vaccines and key considerations that should be taken into vaccine design based on improved understanding of natural H CMV immunity. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 57 REFERENCES
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
TLDR
The zoster vaccine markedly reduced morbidity from herpes zoster and postherpetic neuralgia among older adults and significantly reduced the burden of illness due to herpesZoster. Expand
Herpes zoster and postherpetic neuralgia
TLDR
Management of HZ with antiviral drugs and analgesics produces reasonable results in younger patients, in whom the disease is usually milder, and is effective against acute pain and skin rash, however, it is much less effective against PHN, which occurs more commonly and more severely in older patients. Expand
Advances in the understanding of the pathogenesis and epidemiology of herpes zoster.
TLDR
An overview of the emerging understanding of the epidemiology and pathogenesis of varicella and HZ is provided, in addition to exploring the current theories on latency and reactivation. Expand
Zoster vaccine: current status and future prospects.
  • M. Oxman
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2010
TLDR
Induction of VZV-specific cell-mediated immunity and not antibody should be used as a proxy for the clinical efficacy of new formulations and uses of zoster vaccine. Expand
Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.
TLDR
The HZ/su vaccine significantly reduced the risk of herpes zoster in adults who were 50 years of age or older and was similar to that in the other two age groups. Expand
Characterization of the Host Immune Response in Human Ganglia after Herpes Zoster
TLDR
This is the first report defining the nature of the immune response in ganglia following herpes zoster and provides evidence for persistence of non-latency-associated viral antigen and inflammation beyond rash resolution. Expand
Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).
TLDR
Zoster vaccine is recommended for all persons aged > or =60 years who have no contraindications, including persons who report a previous episode of zoster or who have chronic medical conditions, and the vaccine was partially efficacious at preventing zoster. Expand
Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults.
TLDR
GE-specific cellular and humoral immune responses persisted for 6 years after two-dose vaccination with HZ/su in healthy older adults. Expand
Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial.
TLDR
Live attenuated VzV vaccine caused a significant increase in VZV-CMI in a healthy, elderly population, and the increase of these CMI parameters did not depend upon the titer of virus injected. Expand
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.
  • K. Schmader, M. Levin, +12 authors J. Parrino
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2012
TLDR
In subjects aged 50-59 years, the ZV significantly reduced the incidence of HZ and was well tolerated, with the difference primarily due to higher rates of injection-site AEs and headache. Expand
...
1
2
3
4
5
...